Literature DB >> 26087817

Antipsychotic-induced akathisia in delirium: A systematic review.

Fernando Espi Forcen1, Konstantina Matsoukas1, Yesne Alici1.   

Abstract

OBJECTIVE: Akathisia is a neuropsychiatric syndrome characterized by subjective and objective restlessness. It is a common side effect in patients taking antipsychotics and other psychotropics. Patients with delirium are frequently treated with antipsychotic medications that are well known to induce akathisia as a side effect. However, the prevalence, phenomenology, and management of akathisia in patients with delirium remain largely unknown. The purpose of this review was to examine the medical literature in order to establish the current state of knowledge regarding the prevalence of antipsychotic-induced akathisia in patients with delirium.
METHOD: A systematic review of the literature was conducted using the EMBASE, MEDLINE, PsycINFO, and CINAHL databases. Ten studies addressing the incidence of akathisia in patients taking antipsychotic medication for delirium were identified and included in our review.
RESULTS: The included studies reported a variable prevalence of antipsychotic-induced akathisia. A higher prevalence was found in patients taking haloperidol. Among atypical antipsychotics, paliperidone and ziprasidone were associated with a higher risk of akathisia. The risk for akathisia appeared to be a dose-related phenomenon. SIGNIFICANCE OF
RESULTS: Studies using specific scales for evaluation of akathisia in delirium are lacking. Some populations, such as patients with cancer or terminally ill patients in palliative care settings taking antipsychotics for the treatment of delirium, could be at higher risk for development of akathisia as a side effect.

Entities:  

Keywords:  Akathisia; Antipsychotics; Delirium

Mesh:

Substances:

Year:  2015        PMID: 26087817      PMCID: PMC5516628          DOI: 10.1017/S1478951515000784

Source DB:  PubMed          Journal:  Palliat Support Care        ISSN: 1478-9515


  35 in total

1.  Lad Haskovec and akathisia: an introduction.

Authors:  G E Berrios
Journal:  Hist Psychiatry       Date:  1995-06

Review 2.  First do no harm... Terminal restlessness or drug-induced delirium.

Authors:  Clare White; Mary Ann McCann; Neil Jackson
Journal:  J Palliat Med       Date:  2007-04       Impact factor: 2.947

3.  The Hillside Akathisia Scale: a reliability comparison of the English and German versions.

Authors:  W W Fleischhacker; C H Miller; P Schett; C Barnas; H Ehrmann
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Study on the efficacy and tolerability of amisulpride in medical/surgical inpatients with delirium admitted to a general hospital.

Authors:  L Pintor; E Fuente; E Bailles; S Matrai
Journal:  Eur Psychiatry       Date:  2009-08-19       Impact factor: 5.361

5.  Akathisia variants and tardive dyskinesia.

Authors:  T R Barnes; W M Braude
Journal:  Arch Gen Psychiatry       Date:  1985-09

Review 6.  Evidence-based treatment of delirium in patients with cancer.

Authors:  William Breitbart; Yesne Alici
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

7.  Use of haloperidol infusions to control delirium in critically ill adults.

Authors:  M G Seneff; R A Mathews
Journal:  Ann Pharmacother       Date:  1995 Jul-Aug       Impact factor: 3.154

Review 8.  Clozapine use in children and adolescents.

Authors:  Nitin Gogtay; Judith Rapoport
Journal:  Expert Opin Pharmacother       Date:  2008-02       Impact factor: 3.889

9.  Controlled study of extrapyramidal reactions in the management of delirious, medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines.

Authors:  M A Menza; G B Murray; V F Holmes; W A Rafuls
Journal:  Heart Lung       Date:  1988-05       Impact factor: 2.210

10.  Antipsychotics for delirium in the general hospital setting in consecutive 2453 inpatients: a prospective observational study.

Authors:  Kotaro Hatta; Yasuhiro Kishi; Ken Wada; Toshinari Odawara; Takashi Takeuchi; Takafumi Shiganami; Kazuo Tsuchida; Yoshio Oshima; Naohisa Uchimura; Rie Akaho; Akira Watanabe; Toshihiro Taira; Katsuji Nishimura; Naoko Hashimoto; Chie Usui; Hiroyuki Nakamura
Journal:  Int J Geriatr Psychiatry       Date:  2013-06-25       Impact factor: 3.485

View more
  5 in total

1.  Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.

Authors:  Koen Demyttenaere; Johan Detraux; Giorgio Racagni; Kristof Vansteelandt
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

2.  Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.

Authors:  Maria Juncal-Ruiz; Mariluz Ramirez-Bonilla; Jorge Gomez-Arnau; Victor Ortiz-Garcia de la Foz; Paula Suarez-Pinilla; Obdulia Martinez-Garcia; Karl David Neergaard; Rafael Tabares-Seisdedos; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

3.  Antipsychotic-induced akathisia in cancer settings.

Authors:  Fernando Espi Forcen; James C Root; Yesne Alici
Journal:  Psychooncology       Date:  2016-09-06       Impact factor: 3.894

4.  Antipsychotic Drug Dispensations in Older Adults, Including Continuation After a Fall-Related Hospitalization: Identifying Adherence to Screening Tool of Older Persons' Potentially Inappropriate Prescriptions Criteria Using the Nova Scotia Seniors' Pharmacare Program and Canadian Institute for Health's Discharge Databases.

Authors:  Shanna C Trenaman; Barbara J Hill-Taylor; Kara J Matheson; David M Gardner; Ingrid S Sketris
Journal:  Curr Ther Res Clin Exp       Date:  2018-08-31

Review 5.  Central Nervous System Manifestations Associated with COVID-19.

Authors:  Afshin A Divani; Sasan Andalib; José Biller; Mario Di Napoli; Narges Moghimi; Clio A Rubinos; Christa O'Hana Nobleza; P N Sylaja; Michel Toledano; Simona Lattanzi; Louise D McCullough; Salvador Cruz-Flores; Michel Torbey; M Reza Azarpazhooh
Journal:  Curr Neurol Neurosci Rep       Date:  2020-10-30       Impact factor: 5.081

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.